SQLite Web: event

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.nasdaq.com/articles/viking-therapeutics-ultimate-millionaire-maker-obesity-stock-2026","as_of":"2026-04-17T11:14:13.026874+00:00","canonical_url":"https://www.fool.com/investing/2026/04/17/is-viking-therapeutics-the-ultimate-millionaire-ma/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/viking-therapeutics-ultimate-millionaire-maker-obesity-stock-2026","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_a795d77ad7e24968","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/17/is-viking-therapeutics-the-ultimate-millionaire-ma/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-17T22:25:47.431714+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsViking Therapeutics aims to participate in the billion-dollar obesity market.","fetched_title":"Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026? | Nasdaq","final_url":"https://www.nasdaq.com/articles/viking-therapeutics-ultimate-millionaire-maker-obesity-stock-2026","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/viking-therapeutics-ultimate-millionaire-maker-obesity-stock-2026","source_event_id":"evt_b7ef7cb2a7ef","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"6e0713cf090164b2","kind":"unusual_volume","published_at":"2026-04-17T09:30:00+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.62,"dates_mentioned":["February 2024"],"entities":[{"asset_class":"equity","name":"Viking Therapeutics","relevance":"high","symbol":"VKTX","type":"company"},{"asset_class":"equity","name":"Eli Lilly","relevance":"medium","symbol":"Lilly (not specified)","type":"company"},{"asset_class":"equity","name":"Novo Nordisk","relevance":"medium","symbol":"Novo (not specified)","type":"company"},{"asset_class":"biotech_pipeline","name":"VK2735","relevance":"high","symbol":"VK2735","type":"drug_candidate"},{"asset_class":"biotech_product","name":"Zepbound","relevance":"medium","symbol":"Zepbound","type":"drug"},{"asset_class":"biotech_product","name":"Wegovy","relevance":"medium","symbol":"Wegovy","type":"drug"}],"event_type":"other","information_gaps":["No unusual volume ratio vs average is provided in the provided text (baseline volume, volume ratio, and direction are missing).","No explicit statement confirms whether any volume spike is confirmed by news versus unexplained trading.","The article does not identify a specific current-day catalyst tied to the (unspecified) unusual volume event; it only discusses general catalysts (late-stage trial progress and prior clinical-news-driven surges).","The year for the \u201cthird quarter of this year\u201d oral phase 3 timing is not explicitly stated in the excerpt."],"key_facts":["Viking Therapeutics is described as specializing in metabolic diseases.","The article states an ongoing phase 3 trial for injectable VK2735.","The article states the oral candidate is set to enter phase 3 in the third quarter of the current year (year not explicitly stated).","The article claims the injectable trial completed enrollment ahead of schedule.","The article states Viking stock surged 121% in one trading session after encouraging phase 2 news for VK2735 reported in February 2024.","The article states Viking has \u201cslipped\u201d since that early-2024 surge and suggests there may be room to run on further progress.","The article states Zepbound brought in more than $4 billion in the recent quarter (exact quarter not specified)."],"numeric_claims":[{"label":"VK2735 phase 2 news surge","value":"121% in one trading session (February 2024)"},{"label":"Zepbound revenue","value":"more than $4 billion in the recent quarter"}],"primary_claim":"Viking Therapeutics (VKTX) has an ongoing phase 3 trial for its injectable obesity candidate VK2735 and an oral candidate planned to enter phase 3 in the third quarter, and the stock has previously surged on positive phase 2 news.","relevance_score":0.35,"sentiment":"mixed","source_quality":"high","summary":"The article discusses Viking Therapeutics (NASDAQ: VKTX) as a potential obesity-market entrant, highlighting late-stage trials and prior stock surges on positive clinical news. It does not provide any specific unusual trading volume ratio or quantify the current volume delta.","topics":["obesity","GLP-1","clinical trials","phase 3","stock performance","biotech investment thesis"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsViking Therapeutics aims to participate in the billion-dollar obesity market.","tickers":[],"title":"Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?","url":"https://www.fool.com/investing/2026/04/17/is-viking-therapeutics-the-ultimate-millionaire-ma/"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — signals

Update row sig_4dbbc199dce6 in signals